- Business Wire•1 hour ago
Robbins Arroyo LLP: Insys Therapeutics, Inc. (INSY) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Insys Therapeutics, Inc. in the U.S. District Court for the Southern District of New York.
- Investopedia•9 hours ago
The DEA has approved Syndros, an oral drug for chemotherapy and AIDs patients, as a Schedule II drug.
- TheStreet.com•11 hours ago
Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
INSY : Summary for Insys Therapeutics, Inc. - Yahoo Finance
INSYS Therapeutics, Inc. (INSY)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||10.50 x 1200|
|Ask||10.99 x 200|
|Day's Range||10.41 - 11.69|
|52 Week Range||8.70 - 19.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||33.77|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|